Gilead Expands HIV Prevention Access in Latin America via PAHO Partnership — Gilead Sciences, Inc.

Event summary

Gilead and PAHO agreed to accelerate access to twice-yearly lenacapavir for HIV prevention across 14 Latin American and Caribbean countries.
The deal leverages PAHO’s Regional Revolving Funds to support country-led adoption and implementation efforts.
Lenacapavir is approved in multiple countries for both HIV prevention and treatment of multi-drug-resistant HIV.
Gilead aims to expand its no-profit supply program to reach up to 3 million people through 2028.
The partnership complements existing generic access pathways and voluntary licensing agreements in the region.

The big picture

This partnership aligns with Gilead's global strategy to expand access to long-acting HIV prevention, addressing rising infection rates in Latin America and the Caribbean. The deal underscores the growing importance of regional health organizations in coordinating pharmaceutical access, particularly for chronic conditions requiring sustained treatment. With lenacapavir's unique mechanism of action and long-acting formulation, Gilead is positioning itself as a leader in HIV prevention innovation, though success will depend on effective implementation through PAHO's framework.

What we're watching

Regional Adoption: The pace at which PAHO Member States integrate lenacapavir into national HIV prevention strategies will determine the partnership's impact.
Execution Risk: Gilead's ability to manage logistics and coordination across 14 countries presents operational challenges that could affect rollout timelines.
Competitive Dynamics: Whether this partnership will pressure other pharmaceutical companies to enhance their own HIV prevention access initiatives in the region.